- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03858270
Inhibition of α-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine
June 29, 2020 updated by: Edwin George, MD, PhD, Wayne State University
Lewy Body Dementia (LBD), is the second most common form of dementia after Alzheimer's Disease.
Dementia is defined as a serious loss in cognitive ability due to damages or disease in the brain beyond what is normal aging.
With Lewy Body Dementia, protein deposits, or Lewy Bodies, accumulate in nerve cells throughout the brain, affecting motor control, memory and thinking.
LBD can also form with the progression of Parkinson's disease (PD).
PD is a degenerative nervous system disorder that affects movement ability.
Using more sensitive MRI imaging techniques the investigators are attempting to see if disease progression can be monitored more closely.
At the same time, the study medication Memantine will be compared to a placebo to determine if it can be used to slow the progression of PD.
The purpose of this study is to assess if disease progression can be better monitored through brain imaging and if Memantine will help slow disease progression.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
50
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Melody Hackett, BS
- Phone Number: 313-966-0473
- Email: mgilroy@med.wayne.edu
Study Locations
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Recruiting
- Wayne State University
-
Contact:
- Melody Hackett, BS
- Phone Number: 313-966-0473
- Email: mgilroy@med.wayne.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
45 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosed with idiopathic PD for at least 2 or more years
- 45 to 85 years of age
- Have been on stable doses of anti-Parkinson medication
- Able to give informed consent
- Able to undergo brain MRI
- Unilateral symptoms
- A score of 26 or greater on the Montreal Cognitive Assessment (MOCA), a measure of a patients short-term memory recall, the ability to determine visual-spatial relationships of objects, attention, concentration, working memory, language and orientation to time and place
- Use of one method of medically approved contraceptive
Exclusion Criteria:
- History of any surgical intervention for treating PD (i.e. deep brain stimulation)
- Extreme physical disability
- History or current diagnosis of unstable psychiatric condition
- Presence of dementia or any other condition that prevents the ability of the participant to provide fully informed consent
- Other brain disease
- Treatment with Memantine 30 days prior to baseline
- Females who are pregnant or nursing
- Presence of interacting medications with Memantine or co-morbid medical conditions that may be exacerbated by this agent
- Moderately significant drug interactions with Dextromethorphan, Amantadine, Sodium Bicarbonate, and Acetazolamide
- Previous Allergic reaction to Memantine
- Any genetic form of PD
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Memantine
Memantine will be started at 10 mg tablet once/day for a week at bedtime.
After one week Memantine will be administered at 10 mg tablet twice/day for 51 weeks.
|
Memantine will be started at 10 mg tablet once/day for a week at bedtime.
After one week Memantine will be administered at 10 mg tablet twice/day for 51 weeks.
Other Names:
|
Placebo Comparator: Placebo
Placebo will be started at 10 mg tablet once/day for a week at bedtime.
After one week placebo will be administered at 10 mg tablet twice/day for 51 weeks.
|
Placebo will be started at 10 mg tablet once/day for a week at bedtime.
After one week Placebo will be administered at 10 mg tablet twice/day for 51 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Rey Auditory Verbal Learning Test (RAVLT) Scores (baseline to year-1)
Time Frame: Change from baseline RAVLT at year 1
|
Investigate the effects of Memantine administration on the global cognitive status and executive function
|
Change from baseline RAVLT at year 1
|
Change in Trail test performance time (baseline to year-1)
Time Frame: Change from baseline Trail test at year 1
|
Investigate the effects of Memantine administration on visual attention and task switching
|
Change from baseline Trail test at year 1
|
Change in Stroop Color Word Test performance (baseline to year-1)
Time Frame: Change from baseline Stroop Color Word Test at year 1
|
Investigate the effects of Memantine administration on cognitive interference and processing speed
|
Change from baseline Stroop Color Word Test at year 1
|
Change Judgment of Line Orientation test performance score (baseline to year-1)
Time Frame: Change from baseline Judgment of Line Orientation test at year 1
|
Investigate the effects of Memantine administration on visuospatial skills
|
Change from baseline Judgment of Line Orientation test at year 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the Intracellular volume (ICV), as measured by MRI NODDI sequence, in multiple brain regions, baseline to year-1.
Time Frame: Change from baseline to year-1 of ICV for each brain region mentioned above.
|
ICV component is calculated from the NODDI MRI, using available software, for dorsolateral prefrontal cortex, precuneous, anterior cingulate, posterior cingulate, hippocampus, entorhinal cortex, thalamus, caudate, putamen, association visual cortex, and primary visual cortex.
The change in ICV fro each region will be calculated from baseline to year-1, and would constitute a regional outcome measure, but due to the number of regions, they have all been described under outcome#5, since they have the same unit of measurement.
Group comparisons (i.e.
placebo v. memantine for each region) will be corrected for multiple comparisons as appropriate (E.g Bonferroni )
|
Change from baseline to year-1 of ICV for each brain region mentioned above.
|
Change in the mean kurtosis (MK), an index of tissue complexity, as measured by MRI diffusion kurtosis (DKI) sequence sequence, in multiple brain regions (mentioned in outcome #5), baseline to year-1.
Time Frame: Change from baseline to year-1 of MK for each brain region mentioned above.
|
MK is calculated from the DKI MRI, using available software, for regions mentioned in outcome #5.
The change in MK from each region will be calculated from baseline to year-1.
Group comparisons (i.e.
placebo v. memantine for each region) will be corrected for multiple comparisons as appropriate (E.g Bonferroni )
|
Change from baseline to year-1 of MK for each brain region mentioned above.
|
Change in cortical thickness (Cth), as measured by MRI T1 sequence, in multiple brain regions (mentioned in outcome #5), baseline to year-1.
Time Frame: Change from baseline to year-1 of Cth for each brain region mentioned above.
|
Cth is calculated from T1 MRI, using available software, for regions mentioned in outcome #5.
The change in Cth from each region will be calculated from baseline to year-1.
Group comparisons (i.e.
placebo v. memantine, for each region) will be corrected for multiple comparisons as appropriate (E.g Bonferroni )
|
Change from baseline to year-1 of Cth for each brain region mentioned above.
|
Change in fractional anisotropy (FA), as measured by diffusion tensor imaging (DTI) sequence, in multiple brain regions (mentioned in outcome #5), baseline to year-1.
Time Frame: Change from baseline to year-1 of FA for each brain region mentioned above.
|
Utilizing FA to investigate white matter integrity in corpus callosum, inferior longitudinal fasciculus, and corona radiata.
The change in FA from each region will be calculated from baseline to year-1.
Group comparisons (i.e.
placebo v. memantine, for each region) will be corrected for multiple comparisons as appropriate (E.g Bonferroni )
|
Change from baseline to year-1 of FA for each brain region mentioned above.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2019
Primary Completion (Anticipated)
April 1, 2022
Study Completion (Anticipated)
July 1, 2023
Study Registration Dates
First Submitted
October 2, 2018
First Submitted That Met QC Criteria
February 26, 2019
First Posted (Actual)
February 28, 2019
Study Record Updates
Last Update Posted (Actual)
July 1, 2020
Last Update Submitted That Met QC Criteria
June 29, 2020
Last Verified
June 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Parkinson Disease
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Dopamine Agents
- Antiparkinson Agents
- Anti-Dyskinesia Agents
- Memantine
Other Study ID Numbers
- 09282018
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on Memantine
-
Lyndra Inc.TerminatedHealthy | Gastric RetentionUnited Kingdom
-
Chong Kun Dang PharmaceuticalCompletedAlzheimer's Disease (AD)Korea, Republic of
-
HaEmek Medical Center, IsraelUnknown
-
Merz Pharmaceuticals GmbHLLC Merz Pharma, RussiaCompleted
-
Tianjin Medical University Second HospitalRecruiting
-
GeropharmCompletedBioequivalence, AUC, Cmax, PharmacokineticsRussian Federation
-
H. Lundbeck A/SCompletedAlzheimer Dementia (AD)China
-
University of UtahActive, not recruiting
-
University of Kansas Medical CenterUniversity of Missouri-ColumbiaCompletedAmyotrophic Lateral Sclerosis | Frontal Temporal DementiaUnited States
-
Kenneth Myers, MDCompleted